

Title (en)  
USE OF CD83 IN COMBINATION THERAPIES

Title (de)  
VERWENDUNG VON CB83 IN KOMBINATIONSTHERAPIEN

Title (fr)  
UTILISATION DE CD83 DANS DES POLYTHÉRAPIES

Publication  
**EP 2051987 A4 20110803 (EN)**

Application  
**EP 07811339 A 20070816**

Priority  
• US 2007018048 W 20070816  
• US 83881206 P 20060818  
• US 92737707 P 20070504

Abstract (en)  
[origin: WO2008024242A2] The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of CD83. In some embodiments, CD83 is coadministered to a subject with at least one other immunosuppressive compound. Methods are also provided for generating tolerogenic dendritic cells and regulatory T cells. These cells can be used in vitro to produce additional cells for therapeutic purposes or they can be used in vivo to suppress and/or prevent an undesired immune response. Methods of the invention can be used to prevent or reduce the severity of autoimmune diseases and can also be used to induce tolerance to at least one therapeutic composition, such as a therapeutic protein or transplanted tissue.

IPC 8 full level  
**C07H 21/02** (2006.01); **A01N 37/18** (2006.01); **A01N 61/00** (2006.01); **A61K 31/00** (2006.01); **A61K 35/14** (2006.01); **A61K 38/00** (2006.01); **C07H 21/04** (2006.01)

CPC (source: EP KR US)  
**A61K 9/0019** (2013.01 - KR US); **A61K 9/0053** (2013.01 - KR US); **A61K 31/341** (2013.01 - EP KR US); **A61K 31/365** (2013.01 - KR US); **A61K 31/4353** (2013.01 - EP US); **A61K 31/436** (2013.01 - EP KR US); **A61K 31/5377** (2013.01 - EP KR US); **A61K 35/12** (2013.01 - KR US); **A61K 35/761** (2013.01 - KR US); **A61K 38/13** (2013.01 - KR US); **A61K 38/1709** (2013.01 - KR US); **A61K 38/1774** (2013.01 - EP KR US); **A61K 38/30** (2013.01 - EP KR US); **A61K 38/45** (2013.01 - KR US); **A61K 38/47** (2013.01 - KR US); **A61K 39/3955** (2013.01 - KR US); **A61K 45/06** (2013.01 - EP KR US); **A61K 48/00** (2013.01 - KR); **A61P 37/00** (2018.01 - EP US); **A61P 37/02** (2018.01 - EP); **A61P 37/06** (2018.01 - EP KR US); **A61P 43/00** (2018.01 - EP KR); **C07K 14/70503** (2013.01 - EP KR US); **C07K 16/289** (2013.01 - KR US); **C12Y 204/99** (2013.01 - KR); **C12Y 302/02006** (2013.01 - KR); **A61K 48/00** (2013.01 - EP US); **C12N 2750/14143** (2013.01 - EP KR US); **C12Y 204/99** (2013.01 - EP US); **C12Y 302/02006** (2013.01 - EP US)

C-Set (source: EP US)  
1. **A61K 31/436 + A61K 2300/00**  
2. **A61K 31/5377 + A61K 2300/00**  
3. **A61K 38/1774 + A61K 2300/00**  
4. **A61K 38/30 + A61K 2300/00**

Citation (search report)  
• [XY] US 2004110673 A1 20040610 - STEINKASSERER ALEXANDER [DE], et al  
• [XY] US 2003219436 A1 20031127 - LEDBETTER JEFFREY A [US], et al  
• [Y] WO 9632965 A1 19961024 - RES CORP TECHNOLOGIES INC [US], et al  
• [IY] LECHMANN M ET AL: "Role of CD83 in the immunomodulation of dendritic cells", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, KARGER AG, CH, vol. 129, no. 2, 20 October 2002 (2002-10-20), pages 113 - 118, XP009015843, ISSN: 1018-2438, DOI: 10.1159/000065883  
• [Y] BESSMERTNY ET AL: "94 Tacrolimus (FK-506) and mycophenolate mofetil (MMF) GVHD prophylaxis in allogeneic SCT (alloSCT) recipients: Altered MMF pharmacokinetics (PK) associated with AGVHD", BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, KLUGE CARDEN JENNINGS PUBLISHING, CHARLOTTESVILLE, VA, US, vol. 9, no. 2, 1 February 2003 (2003-02-01), pages 93, XP005433264, ISSN: 1083-8791, DOI: 10.1016/S1083-8791(03)80095-2  
• See also references of WO 2008024242A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2008024242 A2 20080228; WO 2008024242 A3 20081023**; AU 2007288368 A1 20080228; AU 2007288368 B2 20130704; CA 2658000 A1 20080228; CA 2658000 C 20170207; CN 101484461 A 20090715; CN 101484461 B 20140917; CN 104177464 A 20141203; CN 104177464 B 20170412; DK 2051987 T3 20150105; EP 2051987 A2 20090429; EP 2051987 A4 20110803; EP 2051987 B1 20141119; EP 2789625 A1 20141015; EP 2789625 B1 20180606; ES 2526548 T3 20150113; HK 1130263 A1 20091224; HK 1203078 A1 20151016; HK 1204626 A1 20151127; IL 195190 A0 20090803; IL 195190 A 20160421; JP 2010501556 A 20100121; JP 2014193881 A 20141009; JP 5570808 B2 20140813; JP 5898260 B2 20160406; KR 101521197 B1 20150518; KR 20090041366 A 20090428; MX 2008015395 A 20081215; SI 2051987 T1 20150227; US 2014010821 A1 20140109; US 2016008440 A1 20160114; US 2016324926 A1 20161110; US 2023158109 A1 20230525

DOCDB simple family (application)  
**US 2007018048 W 20070816**; AU 2007288368 A 20070816; CA 2658000 A 20070816; CN 200780025011 A 20070816; CN 201410370758 A 20070816; DK 07811339 T 20070816; EP 07811339 A 20070816; EP 14167252 A 20070816; ES 07811339 T 20070816; HK 09109537 A 20091015; HK 15103610 A 20150414; HK 15105179 A 20150530; IL 19519008 A 20081110; JP 2009525563 A 20070816; JP 2014095908 A 20140507; KR 20087032243 A 20070816; MX 2008015395 A 20070816; SI 200731575 T 20070816; US 201514872356 A 20151001; US 201615155287 A 20160516; US 202217806302 A 20220610; US 30830607 A 20070816